Evidence for the use of urinary albumin as marker of kidney involvement in unselected populations

References

• Xue J. L., Ma J. Z., Louis T. A., Collins A. J. Forecast of the number of patients with end‐stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753–8
   PubMed Web of Science ®Google Scholar
• Eknoyan G., Hostetter T., Bakris G. L., Hebert L., Levey A. S., Parving H. H., et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis 2003; 42: 617–22
   PubMed Web of Science ®Google Scholar
• Murray C. J. L., Lopez A. D. Global comparative assessments in the health sector. World Health Organization, Geneva 1994
   Google Scholar
• National Center for Health Statistics. The Third National Health and Nutrition Examination Survey (NHANESIII 1988–94). Reference manuals and reports (CD‐ROM). National Centre for Health Statistics, Hyattsville, Md 1996
   Google Scholar
• Viberti G. C., Hill R. D., Jarret R. J., et al. Predicting diabetic nephropathy in insulin‐dependent patients. N Engl J Med 1984; 311: 89–93
   PubMedGoogle Scholar
• Mogensen C. E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1986; 310: 356–60
   Web of Science ®Google Scholar
• Gosling P., Beevers D. G. Urinary albumin excretion and blood pressure in the general population. Clin Sci 1989; 76: 39–42
   PubMed Web of Science ®Google Scholar
• Cerasola G., Cottone S., D'Ignato G., et al. Micro‐albuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1989; 7(Suppl 6)S332–3
   Google Scholar
• Klausen K. P., Parving H. H., Scharling H., Jensen J. S. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med 2007; 262: 470–8
   PubMed Web of Science ®Google Scholar
• Parving H. H., Lehnert H., Brochner‐Mortensen J. The effect of irbersartin on the development of diabetic nephropathy in patients with type ii diabetes. N Engl J Med 2001; 345: 870–8
   PubMed Web of Science ®Google Scholar
• Zaudbergen A. M. M., Baggen M. G. A., Lamberts S. W. J., et al. Effect of Losartan on microalbuminuria in normotensive patients with Type 2 diabetes mellitus. Ann Intern Med 2003; 139: 90–6
   PubMedGoogle Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with essential treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837–53
   PubMed Web of Science ®Google Scholar
• Taal M. W. Slowing the progression of adult chronic kidney disease. Therapeutic advances. Drugs 2004; 64: 2273–89
   PubMed Web of Science ®Google Scholar
• Fried L. F., Orchard T. J., Kariske B. L. Effect of lipid reduction on the progression of renal disease: a meta‐analysis. Kidney Int 2001; 59: 260–9 [PMID: 11135079]
   PubMed Web of Science ®Google Scholar
• Correa‐Rotter R., Naicker S., Katz I. J., Agarwal S. K., Valdes R. H., Kaseji D., , on behalf of the ISN‐COMGAN Bellagio Study Group 2004, et al. Demographic and epidemiologic transition in the developing world: role of albuminuria in the early diagnosis and prevention of renal and cardiovascular disease. Kidney Int 2004; 66(Suppl 92)S32–7
   Google Scholar
• Garg A. M., Kiberd B. A., Clark W. F., Haynes R. B., Chase C. M. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 2002; 61: 2165–75
   PubMed Web of Science ®Google Scholar
• Brown W. W., Peters R. M., Ohmit S. E., Keane W. F., Collins A., Shu‐Chen C., et al. Early detection of kidney disease in community settings: the kidney early evaluation program. Am J Kidney Dis 2003; 42: 22–35
   PubMed Web of Science ®Google Scholar
• Satko S. G., Freeman B. I. Screening for subclinical nephropathy in relatives of dialysis patients. Semin Dialysis 2001; 14: 311–13
   PubMedGoogle Scholar
• Hillege H. L., Jannsen W. M., Bak A. A., Dieriks G. F., Grobbee D. E., Crijns H. J., et al. Microalbumin is common, also in a non‐diabetic, non‐hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Int Med 2001; 249: 519–26
   PubMed Web of Science ®Google Scholar
• Romundstad S., Holmen J., Kvenild K., Hallan H., Ellekjaer H. The Nord‐Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 42: 466–73
   PubMed Web of Science ®Google Scholar
• Damsgaard E. M., Froland A., Jorgensen O. D., Mogensen C. E. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297–300
   PubMed Web of Science ®Google Scholar
• Hillege H. L., Fidler V., Diercks G. F. H., et al. Urinary albumin excretion predicts cardiovascular and non‐cardiovascular mortality in general population. Circulation 2002; 606: 1777–82
   Google Scholar
• Deckert T., Feldt‐Rasmussen B., Barch‐Johnsen K., et al. Albuminuria reflects widespread vascular damage. The Steno Hypothesis. Diabetologia 1989; 32: 219–26
   PubMed Web of Science ®Google Scholar
• Iseki K., Kinjo K., Iseki C., Takishita S. Relationships between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004; 44: 806–14
   PubMed Web of Science ®Google Scholar
• Halbesma N., Kiuken D. ‐S., Brantsma A. H., Bakker S. J., Wetzels J. F., DeZeeuw D., et al. Macroalbuminuria is a better risk marker than low‐estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006; 17: 2582–90
   PubMed Web of Science ®Google Scholar
• Verhave J. C., Gansevoort R. T., Hillege H. L., Bakker S. J., DeZeeuw D., DeJong P. E., for the PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004; 66(Suppl 9)S18–21
   Google Scholar
• Yamagata K., Yamagata Y., Kobayashi M., Koyama A. A long‐term follow‐up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol 1996; 45: 281–8
   PubMed Web of Science ®Google Scholar
• Asselbergs F. W., Diercks G. F., Hillege H. L., vanBoven A. J., et al. Effects of Fosinopril and Pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809–16
   PubMed Web of Science ®Google Scholar
• McClellan W. M. The epidemic of renal disease – what drives it and what can be done?. Nephrol Dial Transplant 2006; 21: 1461–4
   PubMed Web of Science ®Google Scholar
• Gansevoort R. T., Bakker S. J., de Jong P. E. Early detection of progressive chronic kidney disease: is it feasible?. J Am Soc Nephrol 2006; 17: 1218–20
   PubMedGoogle Scholar
• Chitalia V. C., Kothari J., Wells E. J., Livesey J. H., Robson R. A., Searle M., et al. Cost‐benefit analysis and prediction of 24‐hour proteinuria from the spot urine protein‐creatinine ratio. Clin Nephrol 2001; 55: 436–47
   PubMed Web of Science ®Google Scholar
• Venkat K. K. Proteinuria and microalbuminuria in adults: significance, evaluation, and treatment. Southern Med J 2004; 97: 969–79
   PubMedGoogle Scholar
• Atthobari J., Asselbergs F. W., Boersma C., et al. Cost‐effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the Prevention of Renal and Vascular End‐Stage Disease (PREVEND) Study and the Prevention of Renal and Vascular End‐Stage Disease Intervention Trial (PREVEND IT). Clin Ther 2006; 28: 432–44
   PubMed Web of Science ®Google Scholar